This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry.
Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. They also discuss the details of the special report and share some of the stories behind the numbers.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
A closer look at 2023's top biopharma deals and what lies ahead
A look at pharma revenue rankings
Winning formulas for the best biotech and drug names
[Sponsored] What does the future of specialist distribution look like?
Deep dive: Biopharma layoffs in Q1
The unrecognized threat of PAD
A closer look at European biotech investment in 2024
Inclusivity in psoriasis trials with Takeda
Fierce Medtech's Fierce 15
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success
CAR-T boxed warnings: What comes next?
Breaking down Eli Lilly’s ESG formula
Gene editing's next act
The most anticipated drug launches of 2024
[Sponsored] Turning information into outcomes with MedThink Communications
[Sponsored] Talking technology and collaboration with Cytiva
Navigating the future of medical AI
Closing the $1 trillion women’s health gap
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast
Bloomberg Surveillance